Application 761123

Type
BLA
Sponsor
ASTRAZENECA AB

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761123Saphneloanifrolumab-fnia351(a)Rx2026-06-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001SAPHNELOANIFROLUMAB-FNIAINJECTABLE;INJECTION300MG/2ML(150MG/ML)NoNo

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
SAPHNELOANIFROLUMAB-FNIAAstraZeneca Pharmaceuticals LPd6203302-2128-41a7-b0b4-0e6c0704d4dc2026-04-24Warnings, Adverse reactionsExact identifier
application number: BLA761123
ndc (product): 0310-3040

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 4 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
0310-3040SAPHNELOAnifrolumabAstraZeneca Pharmaceuticals LPBLACurrent
0310-3040SAPHNELOAnifrolumabAstraZeneca Pharmaceuticals LPBLACurrent
0310-3040SAPHNELOAnifrolumabAstraZeneca Pharmaceuticals LPBLACurrent
0310-3040SAPHNELOAnifrolumabAstraZeneca Pharmaceuticals LPBLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
79353SUPPL 2024-08-09
79339SUPPL 2024-08-08
76728SUPPL 2023-12-05
76722SUPPL 2023-12-04
68390ORIG2021-08-17
68261ORIG2021-08-02
68232ORIG2021-08-02